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ABSTRACT
Ewing sarcoma (ES) is the second most frequent bone cancer in childhood and 
is characterized by the presence of the balanced translocation t(11;22)(q24;q12) in 
more than 85% of cases, generating a dysregulated transcription factor EWS/FLI1. 
This fusion protein is an essential oncogenic component of ES development which is 
necessary for tumor cell maintenance and represents an attractive therapeutic target. 
To search for modulators of EWS/FLI1 activity we screened a library of 153 targeted 
compounds and identified inhibitors of the PI3K pathway to directly modulate EWS/
FLI1 transcription. Surprisingly, treatment of four different ES cell lines with BEZ235 
resulted in down regulation of EWS/FLI1 mRNA and protein by ~50% with subsequent 
modulation of target gene expression. Analysis of the EWS/FLI1 promoter region 
(−2239/+67) using various deletion constructs identified two 14bp minimal elements 
as being important for EWS/FLI1 transcription. We identified SP1 as modulator of 
EWS/FLI1 gene expression and demonstrated direct binding to one of these regions 
in the EWS/FLI1 promoter by EMSA and ChIP experiments. These results provide 
the first insights on the transcriptional regulation of EWS/FLI1, an area that has not 
been investigated so far, and offer an additional molecular explanation for the known 
sensitivity of ES cell lines to PI3K inhibition.
INTRODUCTION
Ewing sarcoma (ES) is the second most frequent 
bone cancer in childhood. Clinically, ES appears as 
very aggressive osteolytic tumor with early tendency for 
development of metastasis [1]. It belongs to the group 
of small-round-blue-cell tumors and is comprised of 
largely undifferentiated cells. The unique feature of this 
tumor is the presence of the balanced t(11;22)(q24;q12) 
translocation in more than 85% of cases [2]. This gene 
rearrangement results in expression of a chimaeric 
fusion protein where the RNA binding domain of EWS 
is exchanged by the DNA binding domain of the ETS 
transcription factor FLI1, thus generating an aberrant 
transcription factor EWS/FLI1 [3–6]. More than 18 less 
represented alternative translocations involving EWS and 
other ETS protein family members have been described 
since [7–12].
Extensive evidence supports the notion that 
EWS/FLI1 is an essential oncogenic component of ES 
development. Its oncogenic activity is thought to be 
mediated through inappropriate regulation of target 
genes that are crucial for the fully malignant phenotype 
[5, 6, 13–17]. So far it is not known which of this target 
gene(s) act as crucial oncogenic driver(s). Hence, the 
prevalent hypothesis states that EWS/FLI1 is the major 
genetic mutation that is necessary for development and 
maintenance [18–24] of the tumor although it might not 
be sufficient. Since EWS/FLI1 expression is restricted 
to tumor cells, it represents an ideal therapeutic target. 
However, it acts as transcription factor, which in most 
cases are considered undruggable because of lack of 
enzymatic activity and their direct pharmacological 
inhibition is still challenging. Indeed, EWS/FLI1 behaves 
as intrinsically disordered protein and so far cannot be 
directly targeted by small molecules in a classical sense.
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Therapy of ES today lacks specificity, is ineffective 
against metastasis and bears the potential of serious side 
effects. In the last few decades there has been considerable 
progress in both diagnosis as well as treatment of localized 
disease. However, only 15% of patients with metastatic 
disease survive and therefore this patient group needs 
specific attention. To advance future therapies, one of 
the available options lies in a better understanding of the 
biology of the fusion protein. Considering the difficulties 
in finding direct small molecule inhibitors for transcription 
factors, our aim is to study and characterize the cellular 
processes affecting or being affected by the fusion protein 
and thus providing indirect targeting possibilities. To 
identify molecular pathway(s) that might contribute to 
the transcriptional activity and oncogenic properties of 
EWS/FLI1, we therefore adopted a screening approach 
previously described [25], and screened a small molecule 
library that includes a broad range of protein kinase 
inhibitors covering all major signaling pathways. This 
approach led to the identification of SP1 as a direct 
regulator of EWS/FLI1 transcription through activation 
via the IGF/PI3K/AKT pathway, which is known to play a 
role in Ewing sarcoma [26–32] and whose blockage affects 
cell growth and survival [33–37]. Hence, we identify a 
critical regulatory mechanism upstream of EWS/FLI1.
RESULTS
Screening a library of small molecule inhibitors 
identifies PI3K pathway as modulator of EWS/
FLI1 expression
To identify molecular pathways that may contribute 
to transcriptional activity and oncogenic properties of 
EWS/FLI1, we used the previously established and 
validated strategy [25] to screen a library of small 
molecule inhibitors covering a wide variety of molecular 
pathways. The collection of 153 inhibitors (Supplementary 
Table S1) was screened for EWS/FLI1 target gene 
modulation as primary read out in A673 ES cells at a 
final concentration of 500 nM. EWS/FLI1 transcriptional 
activity was monitored by expression of the known 
target genes pleckstrin homology-like domain, family A, 
member 1-PHLDA1 [25], Nuclear Receptor Subfamily 
0 Group B Member 1-NROB1 [20], NK2 homeobox 
2-NKX2.2 [21] and for EWS/FLI1 itself. Expression 
of PHLDA1 is repressed by EWS/FLI1, in contrast 
to NROB1 and NKX2.2 which are activated. General 
cytotoxicity of the compounds was determined by WST-
1 assay, a colorimetric assay based on the cleavage of a 
tetrazolium salt, to form formazan in viable cells. The final 
hit-list was based on significant (p < 0.05, unpaired two-
tailed t-test) modulation of at least two out of three target 
genes compared to untreated controls in A673 cells. The 
top 16 inhibitory compounds obtained from the screen are 
shown in Table 1 and included inhibitors targeting several 
signaling pathways, both known and unknown to play a 
role in sarcomas. The most prominent among them is the 
phosphoinositide-3-kinase (PI3K) pathway, which was 
affected by three different compounds. Inhibition of this 
pathway provoked a significant modulation of EWS/FLI1 
target genes and a strong inhibition of cell proliferation in 
A673. Hence, these experiments identified PI3K signaling 
to modulate expression of EWS/FLI1 target genes.
Among the PI3K inhibitors tested was BEZ235, 
which is a dual inhibitor of PI3K and the downstream 
mammalian target of Rapamycin (mTOR) that induced 
the most significant modulation of all three EWS/FLI1 
target genes. Hence, we focused on this compound to 
further characterize modulation of EWS/FLI1 activity by 
the PI3K-mTOR pathway. Interestingly, upon treatment of 
four ES cell lines with 500 nM BEZ235 we observed a 
decrease of more than 50% of EWS/FLI1 mRNA levels 
itself (Figure 1A) that also resulted in a reduction of EWS/
FLI1 protein levels (Figure 1B, 1C and Supplementary 
Figure S1) As expected, decrease of EWS/FLI1 mRNA led 
to modulation of target gene expression as well (NKX2.2, 
NROB1 and PHLDA1). Additional target genes such as 
insulin-like growth factor binding protein 3- IGFBP3 [19] 
and Lysyl Oxidase -LOX [38], repressed by EWS/FLI1, 
and six transmembrane epithelial antigen of the prostate 
1-STEAP1 [39] and protein kinase C Beta -PRKCB [40], 
activated by EWS/FLI1, were found to be modulated as 
well (Supplementary Figure S2A–S2D).
Therefore, this data suggests that PI3K signaling 
is involved in transcriptional regulation of EWS/FLI1 
expression.
BEZ235 treatment induces cell cycle arrest
As described above, treatment with 500 nM 
BEZ235 for 24 hrs resulted in a decrease of EWS/FLI1 
protein levels (Figure 1B and 1C) and as a consequence 
in PHLDA1 upregulation, which in turn led to a dose 
dependent reduction of viable cells compared to non-
treated controls (Supplementary Figure S3A). To verify 
that the drug affected cell proliferation we stained the 
cells with crystal violet after drug treatment with 500 nM 
BEZ235 for 24 and 48 hrs. We observed a reduction of 
cell numbers by 40% and 70% compared to the DMSO 
control in A673 and 48% and 77% in SKNMC cells. 
Nevertheless, reduction in cell numbers was much more 
pronounced when cells were treated with Staurosporin 
or Nocodazole (Supplementary Figure S3B–S3E). 
Hence, BEZ235 seems to affect cell proliferation 
without decreasing viability. To investigate whether the 
compound induces cell death, we investigated PARP 
cleavage by Western blot. As shown in Figure 1B 
treatment with 500 nM BEZ235 resulted in minor PARP 
cleavage only. Subsequently, we investigated Casp3 and 
7 activity both with the Casp3/7 Glo assay and at protein 
levels (Supplementary Figure S4A and S4B and data not 
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shown). We observed no increase in activity of Casp3/7 
after BEZ235 treatment, in contrast to treatment with 
Staurosporin and Nocodazole used as positive controls 
(increase by 5–6 fold). Hence, BEZ235 treatment did 
not induce apoptosis as measured by caspase activation 
and PARP cleavage. Subsequent cell cycle analysis 
after treatment with 500 nM BEZ235 for 24 and 48 hrs, 
both in A673 and SKNMC cells, revealed an increase 
in the cellular fraction in G1 phase. Indeed, the G1 
population raised by 20% in A673 and 30% in SKNMC 
cells after drug treatment compared to DMSO control 
(Supplementary Figure S5A and S5B). Taken together, 
Table 1: Screening of a small library of targeted compounds identifies PI3K pathway inhibitors as 
modulators of EWS/FLI1
EWS/FLI1 target gene modulation in A673 cells*,**
Compounda Target Company EWS/
FLI1b
PHLDA1 NROB1 NKX2.2 Nr. of sign. 
Target gene 
response**
Proliferationc
NVP-BEZ235
PI3K/mTOR 
inhibitor
Axon 
1281 89 232 65 40 3 58
PIK 75
PI3K/p110 alpha 
inhibitor
Axon 
1334 8 115 9 5 2 54
NPV-BAG956 PI3K/PDK1 inhibitor
Axon 
1282 111 176 83 68 2 68
DBZ
Gamma Secretase 
inhibitor
Axon 
1488 116 183 85 68 3 113
BZ
Gamma Secretase 
inhibitor
Axon 
1487 102 181 88 77 2 115
Vorinostat HDAC inhibitor Cayman 47 185 61 68 3 124
Bosutinib 
(SKI 606)
BCR-ABL/SRC 
inhibitor
Axon 
1407
92 221 84 56 3 121
Tacrolimus Calcineurin inhibitor Axxonra 62 126 71 67 3 106
YM155 Survivin inhibitor Selleck 
1130
25 120 28 46 2 22
LY 2157299 TGF beta inhibitor Axon 
1491
73 153 76 68 2 108
Velcade Proteosome inhibitor Cilag 77 119 17 18 2 45
ICG-001
CBP/Beta-Catenin 
inhibitor
Selleck 
2662 61 109 72 69 2 100
GDC-0449
Hedgehog Pathway 
inhibitor
Selleck 
1082
97 147 86 63 2 114
Tandutinib FLT3 inhibitor Axon 1415 61 137 105 66 2 103
TG101348 JAK2 inhibitor Symansis 59 128 97 77 2 100
NU 1025 PARP inhibitor
Axon 
1370
90 130 87 81 2 120
aTreatment: 500 nM of compound for 24 hrs
bRelative mRNA expression levels of EWS/FLI1 and its target gene in percentage compared to DMSO. Significant values 
are written in bold (p < 0.05, unpaired two-tailed student t-test).
cCell proliferation measurement using WST-1 assay was performed in parallel. Values are shown in percentage of untreated 
control (=100%) and represent mean of 2–4 independent experiments performed in duplicate.
*In % of control (=100%)
**p < 0.05, unpaired two-tailed t-test, significant values written in bold.
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Figure 1: BEZ235 affects EWS/FLI1 levels. A. Relative expression of EWS/FLI1 and its target genes measured by qRT-PCR after 
24 hrs treatment with 500 nM BEZ235. Mean and standard deviation of 3 independent experiments. B. Protein level measured by western 
blot of EWS/FLI1, PHLDA1, PARP and TUBULIN as loading control in biological triplicates. Cells were treated for 24 h with 500 nM 
BEZ235 in A673 (B) and SKNMC cells C. (Numbers on top of the blot represent intensity of EWS/FLI1 bands measured by densitometry, 
indicated as mean compared to control and normalized to tubulin).
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we conclude that BEZ235 treatment induces a cell cycle 
arrest, similar to what has been reported earlier [24]. 
Since the effect of BEZ235 on cell cycle progression 
could be due to inhibition of PI3K pathway or to EWS/
FLI1 reduction, we also investigated the role of EWS/
FLI1 in cell cycle progression. We depleted EWS/FLI1 
both in A673 and SKNMC using 10 nM of siRNA for 48 
hrs and analyzed the cell cycle distribution. Our results 
showed that depletion of EWS/FLI1 does not induce cell 
cycle arrest (Supplementary Figure S6A and S6B), but 
rather provokes a subG1 peak in SKNMC cells. This 
was also validated at protein level where EWS/FLI1 
depletion provoked Casp7 activation and PARP cleavage 
in SKNMC (Supplementary Figure S6D), but not in 
A673 cells (Supplementary Figure S6C). In addition, 
crystal violet staining showed a reduction in cell numbers 
by 40% in SKNMC cells (Supplementary Figure S6F), 
but no effect on A673 cells (Supplementary Figure S6E). 
Taken together these data show that BEZ235 affects cell 
numbers mainly by inducing cell cycle arrest in ES cells.
PI3K protein depletion reduces EWS/FLI1 
expression
To exclude off-target effects of the small molecule 
inhibitor BEZ235, we performed genetic loss-of-function 
experiments using siRNA targeting the catalytic domains 
α, δ and γ of class I PI3Ks in A673 and SKNMC cells. 
Silencing for 48 hrs resulted in down regulation of PI3K α, 
δ and γ mRNA by 75% compared to scrambled control as 
measured by quantitative RT-PCR (Figure 2A). In silenced 
cells PHLDA1 was up regulated by 10 fold, whereas 
target genes NROB1, NKX2.2 and Caveolin1 [41] were 
repressed by 70%, 55% and 45%, respectively (Figure 
2B). Notably, expression of EWS/FLI1 itself was inhibited 
by 65%, whereas only a non-significant alteration of wt 
FLI1, used as negative control, was observed. These 
results were confirmed at the protein level since 48 hrs 
after treatment with PI3K specific siRNAs, EWS/FLI1 
protein expression decreased while PHLDA1 protein 
level increased. As expected, silencing of PI3K decreased 
phosphorylation of its downstream effectors AKT, mTOR 
and S6 ribosomal protein as shown by phospho-specific 
antibodies (Figure 2C). The same result was confirmed 
in SKNMC cells where depletion of PI3Kαγδ led to 
a decrease of EWS/FLI1 protein levels, whereas the 
depletion of each single component did not affect the 
fusion protein (Supplementary Figure S7A). In addition, 
we performed immunofluorescence analysis to confirm 
the reduction of EWS/FLI1 after silencing of the PI3K 
components on the single cell level. As shown in Figure 
2D (lower panel), after silencing of the three subunits, 
EWS/FLI1 is barely detectable anymore. Altogether, these 
results confirm regulation of EWS/FLI1 transcription by 
the PI3K pathway also at the genetic level. To validate that 
the effect on EWS/FLI1 target genes by the compound is 
due to the presence of EWS/FLI1, we performed the same 
assays in prostate cancer cells lacking the fusion protein. 
As shown in Supplementary Figure S7B, target genes of 
EWS/FLI1, while well expressed at endogenous levels in 
this cell type, are not affected by PI3K inhibition.
PI3K signaling controls EWS/FLI1 transcription 
at its promoter
Since levels of wt FLI1 did not change upon 
inhibition of the PI3K pathway while at the same 
time EWS/FLI1 mRNA expression was reduced, we 
hypothesized that this control of EWS/FLI1 transcription 
occurs within the EWS promoter. To test this notion, we 
conducted reporter assays with a plasmid containing the 
2.3 kb promoter of EWS in front of the luciferase gene. 
A673 ES cells were transfected with this construct and 
treated with increasing concentrations of BEZ235 for 
24 hrs (Figure 3A). Interestingly, we observed a dose 
dependent decrease in luciferase activity which was not the 
case for a constitutive promoter thereby excluding effects 
of the compound on stability of luciferase itself. Already 
50 nM of BEZ235 was able to reduce luciferase activity 
by 50% without affecting cell viability implying that 
indeed this promoter region contains a regulatory element 
responsive to PI3K signaling (Figure 3A). To narrow 
down the region of interest we designed several deletion 
constructs and performed reporter assays as before. Even 
the smallest construct of -275bp still responded to BEZ235 
treatment. Hence, a regulatory element must be contained 
within this promoter element (Figure 3B).
To pinpoint further this potential regulatory 
element within the −275/+67 region of the promoter, 
we designed an additional series of deletion constructs 
in which 12–14bp were deleted in the context of the full 
size promoter (Figure 3C). If the responsible regulatory 
element is excised from the promoter we expect to lose 
any difference in luciferase activity upon drug treatment. 
Indeed, two constructs out of 24 did not respond to drug 
anymore, namely deletion 2 and deletion 23 (Figure 3D). 
Interestingly, both deletions also lost basal activity by 
more than 50% (Figure 3C). Therefore, our results suggest 
that inhibition of PI3K pathway affects gene expression of 
EWS/FLI1 mainly via two regions of the EWS promoter.
SP1 is involved in transcriptional regulation of 
EWS/FLI1
Our results point to an unknown transcription factor 
that binds to a specific region in the EWS promoter and 
whose activity can be stimulated by the PI3K pathway. 
Therefore, we used the sequence covered by Del23 to 
identify transcription factor candidates in silico. Using the 
programs Alibaba 2.2 and P-Match based on consensus 
sequences and Genome Browser based on ChIP datasets, 
we identified four potential candidates, C-Rel, YY1, 
Oncotarget28900www.impactjournals.com/oncotarget
NFKB and SP1, all known downstream targets of the 
PI3K pathway (Figure 4A). To determine which of these 
transcription factors might be involved in EWS/FLI1 gene 
expression, we performed siRNA depletion of each of 
the candidates and measured EWS/FLI1 gene expression 
together with its target gene NROB1 by qRT-PCR 
(Figure 4B) Knockdown of SP1 led to a reduction of EWS/
FLI1 levels by 50% compared to control also at protein 
level (Figure 4C and Supplementary Figure S8A, S8B), 
whereas the other candidates did not affect EWS/FLI1 
neither at the level of gene expression nor at protein 
level (Figure 4C and Supplementary Figure S9A–S9D). 
Also in this case, immunofluorescence analysis after SP1 
depletion revealed barely detectable levels of EWS/FLI1, 
further strengthening the previous observation (Figure 4E 
and Supplementary Figure S10A and S10B). The same 
assays have been performed also in prostate cancer cells 
where SP1 depletion did not affect the levels of the target 
genes (Supplementary Figure S8C). To further validate 
our observations, we combined the knockdown of SP1 
Figure 2: Modulation of EWS/FLI1 and target genes after PI3K pathway silencing. A. PI3K α, γ, and δ mRNA expression 
levels were measured in A673 cells after silencing for 48 hrs compared to scrambled control by qRT-PCR. B. EWS/FLI1 and its target genes 
mRNA expression upon silencing of PI3K α, γ, and δ in A673 cells for 48 hrs. C. Expression levels of EWS/FLI1, PHLDA1 and PI3K 
downstream effectors after silencing in A673 cells for 48 hrs in biological duplicate (numbers on the top of the blot represent intensity of 
EWS/FLI1 bands measured by densitometry). D. Immunofluorescence assessment of FLI1 after silencing for 48 hrs of PI3Kαγδ; scrambled 
as control and FLI1 knock down as positive control. All the assays have been performed 3 times, shown are representative experiments.
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with 500 nM BEZ235 treatment for 24 hrs and observed 
an additive reduction of EWS/FLI1 levels (Figure 5A 
and 5B) both at gene expression and at protein level. 
Taken together we conclude that PI3K pathway regulates 
gene expression of EWS/FLI1 through SP1 activity.
To better understand the relation between the PI3K 
pathway and SP1 in ES cells, we investigated whether 
its activity is modulated by PI3K signaling. Since knock 
down of PI3K αγδ subunits induces a similar decrease of 
EWS/FLI1 mRNA and protein as depletion of SP1 (Figure 
4D and 4F), we hypothesized that PI3K could directly 
affect SP1 levels. Since SP1 is a transcription factor and 
it is mainly located in the nucleus, we investigated SP1 
protein levels after treatment for 24 and 48 hrs with either 
BEZ235 or Rapamycin, an inhibitor of the mTORC1 
complex, in the nuclear fraction. Indeed, we observed 
a clear decrease of SP1 protein (Figure 6A and 6B). 
This was confirmed by immunofluorescence stainings 
showing a clear decrease of SP1 levels after 500 nM 
BEZ235 treatment also in a non-Ewing cell line such 
as human foreskin fibroblasts-HFF (Figure 6C). These 
results suggest that inhibition of PI3K pathway reduces 
SP1 activity, most likely via phosphorylation dependent 
mechanisms.
SP1 directly binds to the Del23 region
To demonstrate direct binding of SP1 to the 
Del23 region of the EWS/FLI1 promoter, we performed 
electrophoretic mobility shift assays using biotinylated 
double strand oligonucleotides covering the DNA 
sequence of Del23 (Figure 7A). Addition of nuclear extract 
produced a shift that could be competed by addition of 
an excess of unlabeled Del23 oligonucleotide (Figure 
7B, lanes 2, 3), indicating that the Del23 region is indeed 
bound by protein. This shift could also be competed 
with an SP1 specific oligonucleotide (lane 4) as well as 
with a specific antibody against SP1 (lane 5), but not by 
addition of a control antibody (actin, lane 6). Specificity 
of the assay was further validated with a mutant Del23 
Figure 3: EWS/FLI1 promoter analysis by luciferase assay. A. Relative luciferase activity in A673 cells transfected with different 
constructs (pGL4.19-empty vector control, pGL3- constitutive promoter control, EWSR1-Luc- 2.3kb promoter vector) upon treatment for 
24 hrs with different concentration of BEZ235. B. Relative luciferase activity in A673 cells transfected with different deletion constructs 
of EWS/FLI1 promoter. Cells were treated with either DMSO or 50 nM BEZ235 C. Luciferase assay performed as above, with a series of 
deletion constructs of the 2.3kb EWS/FLI1 promoter D. Sequences of the two minimal binding elements that are absent from the deletion 
constructs Del2 and Del23 Mean and standard deviation of 3 independent experiments.
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oligonucleotide that generated a faint but unspecific shift 
(lane 8, 9) and with an SP1 specific oligonucleotide that 
could be displaced with the SP1 specific antibody (lane 13) 
similar to Del23. Since also Del2 has been implemented 
in EWS/FLI1 gene expression by the reporter assays and 
since also this region is GC rich, we tested Del2 in gel 
shift experiments as well. Del2 oligonucleotide produced 
a shift that could be competed with unlabeled oligo but not 
Figure 4: SP1 knock down affects EWS/FLI1 levels. A. List of candidates which may bind the Del23 region of the promoter of 
EWS/FLI1 identified by Alibaba 2.2, Genome Browser and P-Match programs. B. siRNA mediated knock down for 48 hrs of candidate 
transcription factors to determine mRNA expression of EWS/FLI1 and target genes (via qRT-PCR). C. EWS/FLI1 protein level after 
silencing for 48 hrs of the candidate transcription factors by siRNA. D. siRNA mediated knockdown of PI3K components in order to 
determine mRNA expression of EWS/FLI1, and SP1 (via qRT-PCR) after 48 hrs. E. Immunofluorescence assessment of FLI1 after 
silencing of SP1 for 48 hrs. F. EWS/FLI1 protein level measured by western blot after 48 hrs reverse silencing of PI3K single subunits and 
combinations. Shown are representative experiments (n = 3).
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by addition of the SP1 antibody (lane 15, 17). Hence, these 
experiments suggest that the Del23 region of the EWS/
FLI1 promoter is bound specifically by SP1 that does not 
bind to the Del2 sequence.
To verify this notion, we performed chromatin 
immunoprecipitation assays in two different Ewing 
cell lines (A673 and SKNMC) (Figure 7C and 7D). 
Using oligonucleotides spanning the Del23 region of 
the EWS promoter, a fragment could be enriched by 
immunoprecipitation with the SP1 antibody as well as 
with the control H3 antibody, but not with the unspecific 
IgG control. All together, these results indicate that SP1 
indeed binds to the Del23 sequence in the promoter of 
EWS to modulate its transcriptional expression.
DISCUSSION
Despite increasing efforts there are still no targeted 
agents implemented in routine therapy of Ewing sarcoma. 
Recently, several novel targeted approaches have been 
initiated and underwent clinical trials with limited success 
[42–45]. However, most of these efforts involved targeting 
of several enzymes downstream of the EWS/FLI1 fusion 
protein, such as IGF1R, and did not attempt to modulate 
the activity of this likely most crucial factor for ES 
oncogenesis itself.
Here, we conducted a screen of a library of small 
molecule targeted inhibitors affecting a broad range of 
different signaling pathways in order to define potential 
novel nodes directed at the fusion protein. For this, we 
employed the previously described and well established 
screening approach that uses expression of three EWS/
FLI1 target genes, both repressed as well as activated, as 
surrogate markers of EWS/FLI1 activity [25]. As the most 
prominent pathway that was able to modulate EWS/FLI1 
target gene expression the P3IK pathway emerged. This 
came as no surprise, since the importance of the IGFR1-
PI3K-AKT axis has been demonstrated already in numerous 
studies [29, 30, 46–48], and triggered several clinical trials. 
However, using BEZ235, a dual PI3K/ mTOR inhibitor, 
as the most potent compound in our hit list we observed a 
strong decrease in EWS/FLI1 activity and surprisingly this 
occurs as consequence of a reduction at protein and RNA 
level of the fusion protein. In addition, since there was a 
Figure 5: SP1 knock down in combination with BEZ235 treatment affects EWS/FLI1 levels. EWS/FLI1 gene expression l 
A. and protein level B. after silencing of SP1–1 and SP1–2 by siRNA for 48 hrs or BEZ235 treatment for 24 hrs or the combination in A673 
cells. Shown is a representative experiment (n = 3).
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reduction in cell number after treatment, also an effect on 
cell cycle progression has been noticed in agreement with 
Manara et al [34]. We hypothesize that the G1 arrest is 
due to the reduction of EWS/FLI1 levels, whereas further 
depletion causes cell death in SKNMC cells which are 
more sensitive than A673 (Supplementary Figure S6C). 
In agreement with the observed cell cycle arrest, reduced 
tumor growth was observed when mice were treated with 
BEZ235 after engraftment of TC71 ES cells [34], with 
regression induced when combined with vincristine.
Indeed, very little is known about the regulation 
of EWS/FLI1 transcription and even less about fusion 
protein turnover. So far, only one study was conducted that 
implied some possible regulatory regions in the EWSR1 
promoter [49]. However, it has been shown previously that 
inhibition of mTOR by Rapamycin can decrease EWS/
FLI1 protein levels [50] similar to what we observed with 
Rapamycin treatment in A673 cells (Figure 6A).
Inhibition of the PI3K pathway triggered repression 
of EWS/FLI1 transcription also when the pathway 
was genetically inhibited by specific siRNA treatment. 
However, we found that it was not sufficient to deplete 
one PI3K isoform but simultaneous down regulation of 
PI3K catalytic subunits α,γ and δ was necessary. This 
can probably be explained by the lack of mutations in 
any of these subunits in ES. Thus, the application of 
more isoform specific inhibitors might be limited and 
compensatory effects might explain the superior activity 
of BEZ235 from our panel of inhibitors tested.
Several additional inhibitors were identified from 
our screen, most notably two γ-secretase inhibitors. 
However, efforts to genetically verify a potential role 
of Notch receptors in EWS/FLI1 expression were not 
successful. This does not exclude a role of the pathway 
in ES biology as it has been demonstrate already that 
inhibition of notch can trigger neural differentiation of 
ES cells [51]. In addition, the most dramatic reduction 
in cell proliferation was seen with the survivin inhibitor 
YM155. Indeed, survivin protein and mRNA are found 
up regulated in ES cells, its expression constitutes a poor 
Figure 6: BEZ235 treatment affects SP1 levels. Nuclear extracts of A673 and SKNMC cells were analyzed by western blot after 
BEZ235 and Rapamycin treatment for 24 and 48 hrs compared to DMSO control in A673 A. and in SKNMC using an SP1 specific antibody. 
B. Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673 C. in SKNMC cells D. and in HFF E. Shown are 
representative experiments (n = 3).
Oncotarget28905www.impactjournals.com/oncotarget
prognostic marker [52] and genetic knockdown reduced 
proliferation [53].
We used luciferase reporter assays to characterize for 
the first time a direct role of the PI3K-AKT-mTOR pathway 
in transcriptional regulation of the EWS/FLI1 promoter. 
This effect could be narrowed down to a regulatory element 
within the promoter, namely the Del23 region, that was 
bound by the transcription factor SP1 as shown by gel 
shift and ChIP assays. SP1 is ubiquitously expressed, and 
binds to GC rich motifs in general. Nevertheless, SP1 did 
not bind to additional GC-rich regions in the promoter such 
as Del2. SP1 has recently been described to be activated 
Figure 7: SP1 binds specifically to the Del23 region of the EWSR1 promoter. A. Sequence of Del23, Del23 Mutant, Del2, 
Del2 Mutant and SP1 oligo. B. EMSA assay performed with nuclear extract of A673 cells. In lane 3 competitor oligonucleotide for Del23 
was added; in lane 4 and 12 competitor oligonucleotide for SP1. In lane 9 we added Mutant Del23 oligonucleotide, in lane 16 one for 
Del2 and in lane 20 one for Del2 Mutant. In lane 5, 13 and 17 we added Sp1 antibody. In lane 6 we added Actin antibody. C. ChIP assay 
performed in A673 cells (C) and SKNMC cells D. Blank and IGG served as negative control, Input and H3, as positive ones. Shown are 
representative experiments (n = 3).
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via phosphorylation by PI3K Cζ [54] and in addition, SP1 
inhibitors, such as Mithramycin, have notable effect on 
EWS/FLI1 protein activity [55]. Mechanistically, it is still 
not entirely clear how SP1 activity is regulated by the PI3K 
pathway. However, we found that treatment specifically 
reduced SP1 levels, similar to what has been shown 
previously [56]. However, whether direct phosphorylation 
at one of the many known sites of SP1 is responsible for this 
effect, remains to be characterized.
Targeting IGFR1-PI3K-AKT-mTOR signaling has 
shown promising results in Ewing sarcoma [42, 44, 45, 
57]. Our demonstration that inhibition of the pathway 
directly impairs expression of the fusion protein itself 
provides additional support for its therapeutic development 
[58]. Most promising appear to be combinations with other 
targeted agents that might modulate EWS/FLI1 activity 
such as YK-4–279 [59] or epigenetic modifiers that can 
potentially further suppress transcription of the fusion 
protein. Hence, elucidating the transcriptional regulation 
of EWS/FLI1 might provide additional molecular targets 
for this devastating disease.
MATERIALS AND METHODS
Cell lines
Three type 1 (A673, SKNMC, TC71) and two 
type 2 Ewing cell lines (SKES, RDES) were used. TC71 
cells were kindly provided by Prof H. Kovar (St-Anna 
Children’s Hospital, Vienna, Austria) and SKES and 
RDES by Prof. K.L. Schaefer (Institute of Pathology, 
Duesseldorf, Germany), A673, HFF and PC3 cells were 
purchased from the American Type Culture Collection-
ATCC (Manassas, VA, USA). Cells were cultivated 
on 0.2% gelatin coated plates (Sigma-Aldrich, Buchs, 
Switzerland) in RPMI medium (DMEM for PC3 cells) 
supplemented with 10% FCS (Sigma-Aldrich), 1% 
Penicillin/Streptomycin (Thermo Fisher Scientific AG, 
Reinach, Switzerland), 1% L-glutamine (Bioconcept AG, 
Allschwil, Switzerland), at 37°C in 5% CO2.
Screening assay
1.5 × 104 cells were plated in 96-well plates 24 hrs 
prior to treatment. A library of 153 commercially available 
targeted inhibitors was acquired from AxonMedchem 
(Groningen, The Netherlands) and Selleck chemicals 
LLC (Munich, Germany) (See Supplementary Table S1). 
Compounds were added to cells in complete RPMI 
medium at a final concentration of 500 nM for 24 hrs. 
Lysis and subsequent cDNA synthesis was performed 
using AffinityScript QPCR cDNA Synthesis Kit (Agilent 
Technologies AG, Basel, Switzerland, #600559), followed 
by quantitative PCR (qPCR). Cell viability was measured 
in parallel using WST-1 cell proliferation kit (Roche 
Diagnostics AG, Rotkreuz, Switzerland).
Quantitative PCR
Quantitative PCR (qPCR) was performed 
under universal cycling conditions on an ABI 7900 
instrument using commercially available target probes 
and mastermix (all from Thermo Fisher Scientific AG). 
Data were analyzed using SDS 2.2 software (Thermo 
Fisher Scientific AG). CT values were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Relative expression levels of the target genes were 
calculated using the ΔΔCT method. All experiments were 
performed in triplicate and repeated independently at 
least 3 times. Data analysis was done with the GraphPad 
prism software (San Diego, CA, USA) and statistical 
analysis using the Student t-test. Commercially available 
target probes included (Thermo Fisher Scientific AG): 
EWSR1-FLI1:Hs03024807_ft, FLI1:Hs00956709_m1, 
SP1:Hs00916521_m1, PHLDA1:Hs00378285_g1, CAV 1: 
Hs00184697_m1, NKX2.2:Hs00159616_m1, NR0B1: 
Hs03043658_m1, GAPDH:Hs99999905_m1, PIK3α:Hs0 
0907966_m1, PIK3 δ:Hs00192399_m1, PIK3 γ:Hs002770 
90_m1, PRKCB:Hs00176998_m1, LOX:Hs00942480_m1, 
IGFBP3:Hs00365742_g1, STEAP1:Hs00185180_m1.
siRNA treatments
A total of 2 × 106 A673 cells were seeded per 60 
mm dish. On the same day, transfection was carried out 
using LipofectamineRNAi MAX reagent (Thermo Fisher 
Scientific AG) and 10 nM siRNA of FLI1 (5266), SP1_1 
(s13319), SP1_2 (s13320), C-Rel (s11906), NFKB (s9504), 
YY1 (s224779) PI3K α (s10520), PI3K δ (s10530), PI3K 
γ (s10532). As a negative control scrambled siRNA no. 2 
(s4390846) was used. All products were purchased from 
Thermo Fisher Scientific AG. Cells were lysed 48 hrs 
after silencing and subsequent RNA extraction using RNA 
easy mini kit (Qiagen Instruments AG, Hombrechtikon, 
Switzerland) was performed followed by cDNA synthesis 
with RT kit (Thermo Fisher Scientific AG).
Immunoblotting
Cells were washed twice with PBS and harvested 
in lysis buffer containing 50 mM NaH2PO4 (pH 7.5), 150 
mM NaCl, 1% Triton X-100, 1 mM Na3OV4, 5 mM Na-
pyrophosphate, 40 nM NaF, 1 mM EGTA supplemented 
with protease inhibitor cocktail (Complete + 1 mM EDTA, 
Roche Diagnostics AG). For the preparation of nuclear 
fraction cells were lysed in 0.1% NP40, washed twice 
with PBS, centrifuged, and the supernatant discarded. 
The nuclear pellet was lysed in Roti-Load 1X (Carl Roth 
GmbH+Co. KG, Karlsruhe, Germany).
Protein concentration was determined by Bradford 
(Biorad, Reinach, Switzerland) and BCA (Thermo Fisher 
Scientific AG). 10–30 μg of protein extract was resolved 
on 4–12% SDS-PAGE and transferred onto nitrocellulose 
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membrane (Thermo Fisher Scientific AG). Primary 
antibodies were used as follows: anti-FLI1 monoclonal 
antibody (MyBioSource LLC, San Diego, CA, USA, 
1:1000), anti-PARP rabbit polyclonal antibody (Cell 
Signalling Technology, Berverly, MA, USA, 1:1000), anti-
pAKT antibody (Ser473, Cell Signalling, 1:1000), anti-AKT 
antibody (Cell Signalling, 1:1000), anti-PHLDA1 antibody 
(Sigma Aldrich, 1:1000), anti-phospho-mTOR antibody 
(Ser2448, Cell Signalling, 1:1000), anti-mTOR antibody 
(Cell Signalling, 1:1000), anti-phospho-S6 Ribosomal protein 
antibody (Ser235/236, Cell Signalling, 1:2000), anti-S6 
Ribosomal protein antibody (Cell Signalling, 1:1000), anti-
SP1 antibody (Millipore, Billerica, MA, USA, 1:1000) and 
anti-β-tubulin I mouse monoclonal antibody (Sigma-Aldrich, 
dilution 1:40′000). After incubation with the appropriate 
secondary peroxidase-conjugated antibodies (1:1′000), 
detection was performed with the ECL chemiluminescence 
reagent (Amersham Biosciences, Freiburg, Germany).
Luciferase assays
The promoter region of EWS/FLI1 (Ref. sequence 
NM_013986) covering 2.3kb (position -2239/+67 relative 
to the transcription initiation site) was cloned in pGL4.19 
luciferase vector (Promega AG, Madison, WI, USA) 
using Infusion HD cloning kit (Clontech Laboratories, 
Inc Mountain View, CA,USA). With the same approach 
several deletion constructs of the EWS/FLI1 promoter 
were made, namely -1708/+67 -1277/+67, -774/+67, 
-275/+67. Using a site directed mutagenesis kit (Thermo 
Fisher Scientific AG), 24 additional deletion mutants of 
the -275/+67 construct were made (see Supplementary 
Table S2 for a detailed list of the plasmids). All constructs 
were verified by sequencing.
2 × 104 A673 cells per well were plated in 96-well 
plate and transfected 24 hrs later using Jet Prime (Polyplus 
Transfection, Strasbourg, France) with 100 ng of reporter 
construct, or empty vector (pGL4.19) as a negative control. 
For normalization, cells were co-transfected with 10 ng of 
a renilla luciferase plasmid. After 24 hrs cells were treated 
with 50 nM BEZ235 or DMSO. 48 hrs post transfection 
they were lysed and assayed for luciferase activity using the 
Dual Glo luciferase reporter system (Promega AG).
Electrophoretic mobility shift assays
1 × 107 cells were plated, washed once with PBS 
24 hrs later and lysed in Buffer A (10 mM Hepes pH 7.9, 
10 mMKCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 
0.5 mM PMSF) containing 10% NP40. The nuclear pellet 
was transferred to Buffer C (20 mM Hepes pH 7.9, 0.4 
M NaCl, 1 mM DTT, 1x complete Mini-Roche tablet). 
40 μg of nuclear extract, 100 nM of biotinylated oligo, 
4 μM of unlabelled probe, 1 μL of anti-SP1 (Millipore) 
or anti Actin antibodies (Cell Signalling) were mixed. 
Oligonucleotides were ordered from Microsynth AG, 
Balgach, Switzerland) and annealed with Annealing 
Buffer (10 mM Tris, 1 mM EDTA, 50 mM NaCl pH 8.0):
Del23_Forward: AGGAGAGAAAATGGCGTCC 
ACGGGTGATATGGTGAAGCT (biotin);
Del23 mutant_Forward: AGGAGAGAAAAAAA 
AAAAAAAAAGTGAGTATGGTGAAGCT (biotin);
Del2_Forward: CACGCTGAGACCCGCTCACC 
CCGCTCTGGCCC (biotin);
Del23 mutant_Forward: CACGCTGAGAAAAAA 
AAAAAAAGCTCTGGCCC (biotin);
SP1_Forward: AAGCTTATTCGATCGGGCGGGG 
CGAGC (biotin).
ChIP assay
1 × 107 cells were plated and cross-linked after 
24 hrs with 1% formaldehyde (Thermo Fisher Scientific 
AG) for 5–10 minutes at RT. Formaldehyde was quenched 
by adding 125 mM Glycine (Sigma-Aldrich) for 
5 minutes. Cells were collected, washed twice with cold 
PBS and lysed in IP buffer (150 mM NaCl, 50 mM Tris-
HCl (pH 7.5), 5 mM EDTA, 0.5% NP-40, 1.0% Triton 
X-100). The crude extract was washed twice with IP 
buffer and sonicated 15 times for 20s [60]. Samples were 
incubated overnight at 4°C with the anti SP1 (Millipore), 
anti H3 (Cell Signalling) or anti IgG (Cell Signalling) 
antibodies and then immunoprecipitated (Active 
Motif kit). Primers (Microsynth AG) were as follows: 
CGAGTAAGCGGTGGTTCATC (forward).
Immunofluorescence
Cells were washed once with PBS, fixed with 4% 
PFA, washed again with PBS and then with PBS-0.1% 
TritonX. Hereafter, they were incubated overnight with 
the primary antibody - FLI1 (1:50) (Sigma-Aldrich), 
SP1 (1:500) (Millipore), - diluted in PBS-0.1% TritonX 
with 4% Horse Serum (Sigma-Aldrich). Afterwards, cells 
were washed and incubated for 1 hr at room temperature 
with the secondary antibody (1:500) diluted in PBS - 
4% horse serum (Sigma-Aldrich). Cells were washed 
twice with PBS and once with distilled water; one drop 
of Dapi (Vechtashield H-1200, Vector Laboratories, Inc. 
Burlingame, CA, USA) added and analyzed with a Zeiss 
inverted microscope.
Casp3/7 assay
4 × 103 A673 and SKNMC cells, were plated in a 
384 well plate previously coated with 0.2% gelatin. After 
24 hrs, cells were treated with 500 nM BEZ235, 1 μM 
Staurosporin, 100 nM Nocodazole or DMSO as controls. 
24 hrs after treatment Caspase 3/7 reagent (Promega AG) 
was added in each well and luminescence was measured.
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FACS analysis
Treated cells were washed with PBS, collected, 
fixed with 70% Ethanol for 2 hrs on ice and stained with 
PI solution (20 μg/ml PI (Sigma-Aldrich), PBS- 0.1% 
TritonX 200 μg/ml RNAse A for measurement with a 
FACS Canto. Data were analyzed using Flow Jo program 
(Flow Jo LLC., Ashland, OR, USA).
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